Skip to main content
. 2021 Nov 3;113(1):297–307. doi: 10.1111/cas.15170

TABLE 2.

Summary of copy‐number alterations or nucleotide substitution mutations detected in ccRCCs

Copy‐number alterations or nucleotide substitution mutations The number of patients with each mutation
Metastasis All (%, n = 60)
Metastasis‐free (n = 34) Late (≥1 y) (n = 8) Early (<1 y) (n = 18)
1p loss 1 2 3 6 (10.0%)
3p loss 31 8 17 56 (93.3%)
4p loss 1 0 2 3 (5.0%)
4q loss 1 2 6 9 (15.0%)
5p gain 10 5 1 16 (26.7%)
5q gain 18 6 7 31 (51.7%)
6q loss 9 2 3 14 (23.3%)
7 gain 12 4 13 29 (48.3%)
8p loss 8 2 8 18 (30.0%)
9p loss 3 1 7 11 (18.3%)
9q loss 3 2 7 12 (20.0%)
10q loss 8 3 1 12 (20.0%)
12 gain 8 5 5 18 (30.0%)
14q loss 17 3 13 33 (55.0%)
16p gain 3 0 4 7 (11.7%)
16q gain 3 0 1 4 (6.7%)
17p13 loss 1 0 2 3 (5.0%)
18 loss 2 3 2 7 (11.7%)
20 gain 4 3 4 11 (18.3%)
21q loss 1 2 1 4 (6.7%)
22 loss 2 0 2 4 (6.7%)
VHL 28 8 14 50 (83.3%)
PBRM1 14 6 8 28 (46.7%)
SETD2 5 2 6 13 (21.7%)
BAP1 4 1 7 12 (20.0%)
The number of chromosome with CN alterations (median) 3 5 6 4